During the median follow-up period of 54.8 months, 10 patients (22.7%) developed new-onset CV events, and multivariate Cox regression analysis adjusted for sex, age, diabetes, hypertension, BMI, and the presence of PH demonstrated that sclerostin could not predict new-onset CV events (OR 2.69, 95% CI 0.89–8.13, P = 0.08) (Table 4). The gene discussed is SOST; the disease is Hypertension.